Showing results (61-70 of 96) with videos related to
Sort By:
Pageof 10
Blood|July 9, 2009
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2CMaike Schwieger, Andrea Schüler, Martin Forster, et al.NMR in Biomedicine|July 9, 2021
Utility of diffusion MRI characteristics of cervical lymph nodes as disease classifier between patients with head and neck squamous cell carcinoma and healthy volunteersMarianthi-Vasiliki Papoutsaki, Harbir Singh Sidhu, Nikolaos Dikaios, et al.JTO Clinical and Research Reports|October 15, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyMatthew G Krebs, Martin Forster, Margarita Majem, et al.Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib TrialDean A Fennell, Sarah Danson, Penella J Woll, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell CarcinomaMartin Forster, Irene Brana, Antonio L Pousa, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2020
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation StudiesHisham Mehanna, Danny Rischin, Stuart J Wong, et al.BMJ Open|November 27, 2023
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UKKenrick Ng, Rob Metcalf, Joseph Sacco, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib StudyMagnus T Dillon, Lorna Grove, Kate L Newbold, et al.Pageof 10